Carvedilol (as phosphate) 10mg, 20mg, 40mg, 80mg; ext-rel caps. Coreg CR are supplied as hard gelatin capsules in bottles of 30 in the following strengths: 10 mg – white and green capsule shell ...

Flamel might be earning more than had been calculated from its lead drug, but the company still isn't profitable. Flamel gets royalties from sales of heart-disease drug Coreg CR, which it helped ...

The first generic versions of GlaxoSmithKline’s cardiovascular agent Coreg – all 14 of them – have been approved by US regulators. The first generic versions of GlaxoSmithKline’s cardiovascular agent ...

Following a more than decade-long legal back-and-forth over the generic drug carveout practice known as “skinny” labeling, GSK and Teva have put their dispute to bed, new court documents show. In a ...

November 17, 2006 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise on the use of carvedilol tablets in diabetic patients; the risk for potentially fatal ...

Please provide your email address to receive an email when new articles are posted on . Two preparations of carvedilol given to patients with heart failure were found nearly bioequivalent. Researchers ...

Prove it, GlaxoSmithKline. So says a judge in the Coreg patent case that last year ended in a $235 million judgment against generics maker Teva. In the patent "carve-out" case, GSK didn't bring enough ...

Carvedilol is a generic prescription drug that’s used to treat high blood pressure and certain heart conditions. Carvedilol oral tablets are also available as the brand-name drug Coreg. Carvedilol is ...

Carvedilol is a generic drug that’s prescribed for heart failure, high blood pressure, or certain heart problems following a heart attack. It’s available as the brand-name drug Coreg. The cost of ...

The US Food and Drug Administration has approved a label update for GlaxoSmithKline’s Coreg (carvedilol), meaning that the beta-blocker is now available to reduce the risk of suffering a heart attack.

(Reuters) - A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents ...